FDA
-
-
-
-
-
-
-
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
-
-
-
-
-
-
-
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
-
-
-
-
-
-
-
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
-
322,093 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

